2,6-二氯苯丙醇 | 14573-24-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,6-二氯苯丙醇
• 英文名称: 3-(2,6-dichlorophenyl)-1-propanol
• 英文别名: 3-(2,6-dichlorophenyl)propan-1-ol；3-(2,6-Dichlorphenyl)-propan-1-ol
• CAS: 14573-24-1
• 化学式: C₉H₁₀Cl₂O
• 分子量: 205.084
• InChiKey: RFSGMWVMSXVTRO-UHFFFAOYSA-N

物化性质

• 沸点：
  302.0±27.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2906299090

反应信息

• 作为反应物：
  描述：

  2,6-二氯苯丙醇 在 三溴化磷 、 肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 2-[3-(2,6-二氯苯基)丙基氨基]胍
  参考文献：
  名称：

  芳氧基烷基氨基胍。它们的合成和生物学特性。

  摘要：

  DOI：

  10.1021/jm00315a024
• 作为产物：
  描述：

  ethyl 2,6-dichlorocinnamate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以46.9%的产率得到2,6-二氯苯丙醇
  参考文献：
  名称：

  WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVE AND MEDICINE CONTAINING THE SAME

  摘要：

  一种由化学式（1）表示的苯基吡啶嗪衍生物：其中，R1、R2、R3、X、Y、Z和n的定义与规范中相同；或其盐，或包含该化合物的药物。本发明提供了具有出色的抑制白细胞介素-β产生活性、高水溶性和高口服吸收性的水溶性苯基吡啶嗪衍生物和含有它们的药物。

  公开号：

  EP1604984A1

文献信息

• [EN] (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS<br/>[FR] DÉRIVÉS DE (THIO)MORPHOLINE MODULATEURS DE S1P
  申请人：ABBOTT HEALTHCARE PRODUCTS BV

  公开号：WO2011023795A1

  公开（公告）日：2011-03-03

  The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

  本发明涉及公式（I）的（硫）吗啉衍生物，其中R1从氰基，（2-4C）炔基，（1-4C）烷基，（3-6C）环烷基，（4-6C）环烯基，（6-8C）双环烷基，（8-10C）双环基团中选择，每个基团可选择地取代为（1-4C）烷基，苯基，联苯基，萘基，每个基团可选择地取代为一个或多个取代基，独立选择自卤素，（1-4C）烷基可选择地取代为一个或多个氟原子，（2-4C）炔基，（1-4C）氧烷基可选择地取代为一个或多个氟原子，氨基，二（1-4C）烷基氨基，-SO2-（1-4C）烷基，-CO-（1-4C）烷基，-CO-O-（1-4C）烷基，-NH-CO-（1-4C）烷基和（3-6C）环烷基，苯基取代为苯氧基，苄基，苄氧基，苯乙基或单环杂环烃，每个基团可选择地取代为（1-4C）烷基，单环杂环烃可选择地取代为卤素，（1-4C）烷基或取代为苯基的苯基，可选择地取代为（1-4C）烷基，和双环杂环烃可选择地取代为（1-4C）烷基；A从-CO-O-，-O-CO-，-NH-CO-，-CO-NH，-C=C-，-CCH3-O-和连接基-Y-（CH2）n-X-中选择，其中Y连接到R1并从键，-O-，-S-，-SO-，-SO2-，-CH2-O-，-CO-，-O-CO-，-CO-O-，-CO-NH-，-NH-CO-，-C=C-和-C≡C-中选择；n是1到10的整数；X连接到苯基/吡啶基团并从键，-O-，-S-，-SO-，-SO2-，-NH，-CO-，-C=C-和-C≡C-中选择；环结构B可选择地含有一个氮原子；R2是H，（1-4C）烷基可选择地取代为一个或多个氟原子，（1-4C）氧烷基可选择地取代为一个或多个氟原子，或卤素；R3是（1-4C）烷基-R5，其中烷基基团可取代为（CH2）2形成环丙基基团或一个或两个卤素原子，或R3是（3-6C）环烷基-R5或-CO-CH2-R5，其中R5是-OH，-PO3H2，-OPO3H2，-COOH，-COO（1-4C）烷基或四唑-5-基；R4是H或（1-4C）烷基；R6是一个或多个取代基，独立选择自H，（1-4C）烷基或氧代基；W是-O-，-S-，-SO-或-SO2-；或其药学上可接受的盐，溶剂或水合物；但是，公式（I）的衍生物不是2-（4-乙基苯基）-4-吗啉乙醇或4-[4-（2-羟乙基）-2-吗啉基]苯乙腈或其药学上可接受的盐，溶剂或水合物。本发明的化合物具有对S1P受体的亲和力，可用于治疗、缓解或预防S1P受体介导的疾病和症状。
• Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
  申请人：Miyazaki Susumu

  公开号：US20050054645A1

  公开（公告）日：2005-03-10

  The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Becuae it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

  本发明涉及一种由下式[I]所表示的含氮融合环化合物，其中每个符号如规范中定义，或其药学上可接受的盐，以及含有该化合物的抗HIV剂。本发明的化合物具有HIV整合酶抑制活性，并可用作预防或治疗艾滋病的药剂，或作为抗HIV剂。此外，通过与其他抗HIV剂（如蛋白酶抑制剂、逆转录酶抑制剂等）的联合使用，可使其成为更有效的抗HIV剂。由于显示出整合酶特异性高抑制活性，该化合物可作为对人体安全的药物剂，仅引起较少的副作用。
• Water-soluble phenylpyridazine compounds and compositions containing the same
  申请人：Kyotani Yoshinori

  公开号：US06861428B2

  公开（公告）日：2005-03-01

  Compounds having the formula (1): wherein R 1 represents an alkyl or alkenyl group, R 2 and R 3 each independently represents a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or R 2 and R 3 may be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represents a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to pharmaceutical compositions containing them. These compounds have inhibitory activity against IL-1β production, high water solubility and good oral absorbability.

  具有下列式（1）的化合物：其中R1代表烷基或烯基基团，R2和R3各自独立地代表氢原子或烷基、羟基烷基、二羟基烷基或炔基基团，或者R2和R3可以与相邻的氮原子融合在一起形成取代或未取代的含氮饱和杂环基团，X、Y和Z各自独立地代表氢原子、烷基基团、卤素原子或类似物，n代表1到5之间的整数；以及含有它们的药物组合物。这些化合物具有对IL-1β产生的抑制活性，高水溶性和良好的口服吸收性。
• Water-soluble phenylpyridazine derivative and medicine containing the same
  申请人：Kyotani Yoshinori

  公开号：US20060142292A1

  公开（公告）日：2006-06-29

  A phenylpyridazine derivative represented by the formula (1): Wherein, R1, R2, R3, X, Y, Z and n have the same meaning as defined in the specification; or a salt thereof, or a medicine containing the compound. The present invention provides water-soluble phenylpyridazine derivatives and medicines containing them, which have excellent inhibitory activity against interleukin-β production, high water solubility and high oral absorbability.

  一种由式（1）表示的苯基吡嗪衍生物：其中，R1、R2、R3、X、Y、Z和n的含义与说明书中定义的相同；或其盐，或含有该化合物的药物。本发明提供了水溶性苯基吡嗪衍生物及含有它们的药物，它们具有优异的抑制白细胞介素-β产生的活性，高水溶性和高口服吸收性。
• Imidazo[1,2,-A]pyridine ether compounds as ion channel modulators
  申请人：——

  公开号：US20040048885A1

  公开（公告）日：2004-03-11

  Imidazo[1,2-&agr;]pyridine ether compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment or prevention of atrial or ventricular arrhythmia as well as atrial or ventricular fibrillation.

  本发明披露了咪唑[1,2-a]吡啶醚类化合物。本发明的化合物可纳入组合物和套件中。本发明还披露了化合物和组合物的多种体外和体内用途，包括治疗或预防心房或心室心律失常以及心房或心室颤动。